A Study of BRY812 for Injection Alone in Subjects With Advanced Malignancies

This is a Phase I, multicenter, open-label, single-arm and first-in-human clinical study of BRY812 for injection. The study objectives are to evaluate the safety, tolerability, pharmacokinetic profile, anti-tumor activity and immunogenicity of BRY812 for injection in patients with advanced malignancies. Patients will receive treatment every 3 weeks until intolerable toxicity, disease progression, pregnancy, withdrawal of informed consent, death, study discontinuation, or withdrawal from the study.

NCT Number	NCT06038058
Lead Sponsor	BioRay Pharmaceutical Co., Ltd.
Conditions	Advanced Malignancies
Enrollment	164 participants
Start Date	2023-10-10
Primary Completion	2028-08 (estimated)
Study Completion	2028-12 (estimated)
Updated on ClinicalTrials.gov	2025-12-30